DK3290052T3 - Monoklonale antistoffer mod fibroblastvækstfaktorreceptor 2 - Google Patents

Monoklonale antistoffer mod fibroblastvækstfaktorreceptor 2 Download PDF

Info

Publication number
DK3290052T3
DK3290052T3 DK17191118.3T DK17191118T DK3290052T3 DK 3290052 T3 DK3290052 T3 DK 3290052T3 DK 17191118 T DK17191118 T DK 17191118T DK 3290052 T3 DK3290052 T3 DK 3290052T3
Authority
DK
Denmark
Prior art keywords
growth factor
monoclonal antibodies
antibodies against
factor receptor
fibroblast growth
Prior art date
Application number
DK17191118.3T
Other languages
English (en)
Inventor
Jin Kim Kyung
Wei-Meng Zhao
Hangil Park
Original Assignee
Galaxy Biotech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galaxy Biotech Llc filed Critical Galaxy Biotech Llc
Application granted granted Critical
Publication of DK3290052T3 publication Critical patent/DK3290052T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK17191118.3T 2008-11-07 2009-11-06 Monoklonale antistoffer mod fibroblastvækstfaktorreceptor 2 DK3290052T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11268608P 2008-11-07 2008-11-07
US16487009P 2009-03-30 2009-03-30
EP14188785.1A EP2842573B1 (en) 2008-11-07 2009-11-06 Monoclonal antibodies to Fibroblast Growth Factor receptor 2

Publications (1)

Publication Number Publication Date
DK3290052T3 true DK3290052T3 (da) 2020-02-03

Family

ID=42153600

Family Applications (3)

Application Number Title Priority Date Filing Date
DK17191118.3T DK3290052T3 (da) 2008-11-07 2009-11-06 Monoklonale antistoffer mod fibroblastvækstfaktorreceptor 2
DK09825523.5T DK2365828T3 (da) 2008-11-07 2009-11-06 Monoklonale antistoffer mod fibroblastvækstfaktorreceptor 2.
DK14188785.1T DK2842573T3 (da) 2008-11-07 2009-11-06 Monoklonale antistoffer mod fibroblast vækstfaktorreceptor 2

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK09825523.5T DK2365828T3 (da) 2008-11-07 2009-11-06 Monoklonale antistoffer mod fibroblastvækstfaktorreceptor 2.
DK14188785.1T DK2842573T3 (da) 2008-11-07 2009-11-06 Monoklonale antistoffer mod fibroblast vækstfaktorreceptor 2

Country Status (21)

Country Link
US (8) US8101723B2 (da)
EP (4) EP2365828B1 (da)
JP (7) JP5627591B2 (da)
KR (1) KR101699432B1 (da)
CN (1) CN102131524B (da)
AU (1) AU2009313357B2 (da)
BR (1) BRPI0917315B8 (da)
CA (2) CA3166399A1 (da)
DK (3) DK3290052T3 (da)
ES (3) ES2770134T3 (da)
HK (3) HK1160012A1 (da)
HR (2) HRP20171640T1 (da)
HU (1) HUE035700T2 (da)
LT (2) LT3290052T (da)
MX (1) MX2011000455A (da)
NO (1) NO2842573T3 (da)
PL (3) PL2365828T3 (da)
PT (3) PT2842573T (da)
RU (1) RU2546254C9 (da)
SI (2) SI2842573T1 (da)
WO (1) WO2010054265A2 (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9260525B2 (en) 2008-02-04 2016-02-16 Xiao-Jia Chang Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
US20110059091A1 (en) * 2008-02-04 2011-03-10 Xiao-Jia Chang Inhibitors of oncogenic isoforms and uses thereof
PT2842573T (pt) 2008-11-07 2017-12-04 Galaxy Biotech Llc Anticorpos monoclonais para o recetor 2 do factor de crescimento de fibroblastos
WO2011143318A2 (en) * 2010-05-11 2011-11-17 Aveo Pharmaceuticals, Inc. Anti-fgfr2 antibodies
EP2603521A4 (en) * 2010-08-12 2014-10-01 Attogen Inc ANTIBODY MOLECULARS FOR ONGOGEN FIBROBLAST GROWTH RECEPTOR 2 ISOFORMS AND ITS USES
CN107936121B (zh) 2011-05-16 2022-01-14 埃泰美德(香港)有限公司 多特异性fab融合蛋白及其使用方法
AR088941A1 (es) * 2011-11-23 2014-07-16 Bayer Ip Gmbh Anticuerpos anti-fgfr2 y sus usos
MX2014007121A (es) * 2011-12-14 2014-09-04 Seattle Genetics Inc Nuevos conjugados de principio activo-ligante (adc) y su uso.
MX360056B (es) * 2012-03-08 2018-10-19 Janssen Vaccines & Prevention Bv Moléculas de unión humanas que pueden unirse a los virus de la influenza b y neutralizarlos, y sus usos.
JP6188681B2 (ja) * 2012-04-09 2017-08-30 第一三共株式会社 抗ｆｇｆｒ２抗体
WO2014089193A1 (en) * 2012-12-04 2014-06-12 Aveo Pharmaceuticals, Inc. Anti-fgfr2 antibodies
RS58147B1 (sr) * 2012-12-21 2019-02-28 Janssen Biotech Inc Senzitivni višestruki imunotest za rastvorljive receptore faktora rasta fibroblasta
CN103145843B (zh) * 2013-02-20 2014-10-29 暨南大学 抗成纤维细胞生长因子受体的单链抗体
CN105246511A (zh) 2013-03-06 2016-01-13 豪夫迈·罗氏有限公司 治疗和预防癌症药物抗性的方法
SI3027651T1 (sl) * 2013-08-01 2019-05-31 Five Prime Therapeutics, Inc. Afukozilirana protitelesa proti fgfr2iiib
TWI664977B (zh) * 2013-10-08 2019-07-11 第一三共股份有限公司 抗ｆｇｆｒ２抗體及其與其他藥劑之組合
CN103757026B (zh) 2013-12-20 2017-04-05 广州圣露生物技术有限公司 FGFR2b胞外段的基因序列、多肽及其应用
US20230190750A1 (en) 2014-06-13 2023-06-22 Genentech, Inc. Methods of treating and preventing cancer drug resistance
CN104231079A (zh) * 2014-09-12 2014-12-24 暨南大学 一种靶向bFGF高亲和力受体结合位点的抗体及其应用
JP6887944B2 (ja) * 2015-04-08 2021-06-16 第一三共株式会社 抗ｆｇｆｒ２抗体と他剤を含む組成物
US10881734B2 (en) 2015-04-20 2021-01-05 Daiichi Sankyo Company, Limited Monoclonal antibodies to human fibroblast growth factor receptor 2 (HFGFR2) and methods of use thereof
RU2638457C2 (ru) * 2015-09-28 2017-12-13 Общество С Ограниченной Ответственностью "Онкомакс" Антитела, специфически связывающие рецептор 1 типа фактора роста фибробластов, применение антител для лечения онкологического заболевания, способ получения антител
RU2021107536A (ru) 2015-11-23 2021-07-02 Файв Прайм Терапьютикс, Инк. Ингибиторы fgfr2 отдельно или в комбинации с иммуностимулирующими агентами в лечении рака
WO2017157305A1 (en) 2016-03-15 2017-09-21 Generon (Shanghai) Corporation Ltd. Multispecific fab fusion proteins and use thereof
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
EP3624837A1 (en) 2017-05-16 2020-03-25 Five Prime Therapeutics, Inc. Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment
CA3065630A1 (en) 2017-06-02 2018-12-06 Ablynx Nv Aggrecan binding immunoglobulins
WO2019084067A1 (en) * 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. ANTI-CD117 ANTIBODIES AND METHODS OF USE
JP7280254B2 (ja) 2017-10-24 2023-05-23 マジェンタ セラピューティクス インコーポレイテッド Ｃｄ１１７＋細胞を減少させるための組成物及び方法
AU2018354189A1 (en) 2017-10-24 2020-04-23 Crispr Therapeutics Ag Compositions and methods for the depletion of CD117+ cells
JP2022503886A (ja) 2018-10-05 2022-01-12 ファイブ プライム セラピューティクス， インコーポレイテッド 抗ｆｇｆｒ２抗体製剤
AU2020412088A1 (en) * 2019-12-24 2022-06-23 Dizal (Jiangsu) Pharmaceutical Co., Ltd. Novel anti-FGFR2b antibodies
WO2021247718A1 (en) * 2020-06-03 2021-12-09 The Broad Institute, Inc. Antagonistic biparatopic antibodies that specifically bind fibroblast growth factor receptor 2 and methods of using same
KR20230095070A (ko) 2020-10-22 2023-06-28 리제너론 파마슈티칼스 인코포레이티드 항-fgfr2 항체 및 이의 사용 방법
EP4273166A1 (en) * 2020-12-29 2023-11-08 Shenzhen Forward Pharmaceuticals Co., Limited Anti-fgfr2 antibody and use thereof
WO2023056916A1 (zh) * 2021-10-08 2023-04-13 深圳福沃药业有限公司 Adcc增强型抗fgfr2抗体及其用途
TW202342527A (zh) 2022-02-25 2023-11-01 美商安進公司 鱗狀非小細胞肺癌之治療
WO2024067876A1 (en) * 2022-09-30 2024-04-04 3H Pharmaceuticals Co., Ltd. Anti-fgfr2b antibodies and uses thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP3039802B2 (ja) * 1989-07-06 2000-05-08 ザ リージェンツ オブザ ユニバーシティ オブ カリフォルニア 繊維芽細胞成長因子のための受容体
AU633698B2 (en) 1990-01-12 1993-02-04 Amgen Fremont Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5863888A (en) * 1990-07-06 1999-01-26 Rhone-Poulenc Rorer Pharmaceuticals Inc. Human Bek Fibroblast growth factor receptor
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992020791A1 (en) 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
AU3494397A (en) 1996-06-18 1998-01-07 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Fibroblast growth factor receptor activating gene i and related compositions and methods
US20030143676A1 (en) * 1999-03-25 2003-07-31 Genesis Research And Development Corporation Limited Fibroblast growth factor receptors and methods for their use
KR100816572B1 (ko) * 1999-04-28 2008-03-24 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 항-ｖｅｇｆ 항체 및 이를 포함하는 약제학적 조성물
JP2001302699A (ja) 2000-04-17 2001-10-31 Nichirei Corp ヒトｋｇｆｒに対する抗体
US20020115603A1 (en) 2000-06-22 2002-08-22 Chiron Corporation Methods and compositions for the treatment of peripheral artery disease
CA2450285C (en) * 2001-06-13 2016-08-02 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (egfr)
JP2005500034A (ja) 2001-06-20 2005-01-06 プロション バイオテク リミテッド 受容体型タンパク質チロシンキナーゼ活性化を遮断する抗体、そのスクリーニング方法、及びその使用
EP1539233B1 (en) 2001-07-12 2011-04-27 FOOTE, Jefferson Super humanized antibodies
CN100531796C (zh) 2002-01-31 2009-08-26 马普科技促进协会 Fgfr激动剂
KR100493460B1 (ko) * 2002-08-29 2005-06-07 재단법인서울대학교산학협력재단 암 세포에서 발현되는 ｆｇｆｒ2 이성체
US7220410B2 (en) 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
TWI476206B (zh) 2003-07-18 2015-03-11 Amgen Inc 對肝細胞生長因子具專一性之結合劑
US20070248605A1 (en) * 2003-12-19 2007-10-25 Five Prime Therapetutics, Inc. Fibroblast Growth Factor Receptors 1,2,3, and 4 as Targets for Therapeutic Intervention
US7872016B2 (en) * 2004-05-25 2011-01-18 Yale University Method for treating skeletal disorders resulting from FGFR malfunction
WO2007114896A2 (en) 2006-03-31 2007-10-11 Ordway Research Institute Prognostic and diagnostic method for cancer therapy
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
CA2651755A1 (en) * 2006-05-12 2007-11-22 Genentech, Inc. Methods and compositions for the diagnosis and treatment of cancer
SG158112A1 (en) 2006-06-02 2010-01-29 Aveo Pharmaceuticals Inc Hepatocyte growth factor (hgf) binding proteins
EP2029627B1 (en) 2006-06-02 2011-11-16 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (hgf) binding proteins
EP2046384A4 (en) 2006-06-15 2009-12-02 Fibron Ltd ANTIBODIES BLOCKING FIBROBLAST GROWTH FACTOR RECEPTOR ACTIVATION AND METHODS OF USING THE SAME
EP3357932A1 (en) 2006-09-29 2018-08-08 OncoMed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US8394927B2 (en) * 2006-11-03 2013-03-12 U3 Pharma Gmbh FGFR4 antibodies
KR20100015883A (ko) * 2007-03-23 2010-02-12 더 트랜스내셔날 게노믹스 리서치 인스티튜트 자궁내막암 및 전암을 진단，분류 및 치료하는 방법
US20110091473A1 (en) 2007-10-22 2011-04-21 Genmab A/S Novel antibody therapies
US20110059091A1 (en) 2008-02-04 2011-03-10 Xiao-Jia Chang Inhibitors of oncogenic isoforms and uses thereof
EP2177615A1 (en) 2008-10-10 2010-04-21 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases
PT2842573T (pt) 2008-11-07 2017-12-04 Galaxy Biotech Llc Anticorpos monoclonais para o recetor 2 do factor de crescimento de fibroblastos
US20120301482A1 (en) 2009-08-25 2012-11-29 National Jewish Health Methods and compositions for treatment of lung injury

Also Published As

Publication number Publication date
JP2019052165A (ja) 2019-04-04
HK1207974A1 (en) 2016-02-19
US9834609B2 (en) 2017-12-05
US20200347141A1 (en) 2020-11-05
CA3166399A1 (en) 2010-05-14
CA2733668C (en) 2022-08-30
CN102131524A (zh) 2011-07-20
EP2365828A4 (en) 2012-06-06
PL3290052T3 (pl) 2020-06-29
EP3290052B1 (en) 2019-12-25
US20230242650A1 (en) 2023-08-03
NO2842573T3 (da) 2018-02-24
HK1160012A1 (en) 2012-08-10
EP3290052A1 (en) 2018-03-07
AU2009313357A1 (en) 2010-05-14
EP2365828A2 (en) 2011-09-21
BRPI0917315A2 (pt) 2015-11-17
US20160362496A1 (en) 2016-12-15
US8603987B2 (en) 2013-12-10
JP2017019807A (ja) 2017-01-26
CN102131524B (zh) 2014-05-14
JP2022008996A (ja) 2022-01-14
JP7301106B2 (ja) 2023-06-30
JP5627591B2 (ja) 2014-11-19
SI2842573T1 (en) 2018-01-31
KR20110081141A (ko) 2011-07-13
US20100196364A1 (en) 2010-08-05
AU2009313357B2 (en) 2015-06-11
EP2842573A1 (en) 2015-03-04
EP3783024A1 (en) 2021-02-24
EP2365828B1 (en) 2014-10-15
JP6661734B2 (ja) 2020-03-11
ES2523740T3 (es) 2014-12-01
US20140193899A1 (en) 2014-07-10
PT3290052T (pt) 2020-02-06
ES2770134T3 (es) 2020-06-30
JP2023116746A (ja) 2023-08-22
LT3290052T (lt) 2020-02-25
US20190153105A1 (en) 2019-05-23
WO2010054265A3 (en) 2010-09-16
SI3290052T1 (sl) 2020-07-31
PT2842573T (pt) 2017-12-04
RU2011141890A (ru) 2013-04-27
EP2842573B1 (en) 2017-09-27
JP6342223B2 (ja) 2018-06-13
PL2365828T3 (pl) 2015-04-30
HRP20200090T1 (hr) 2020-04-03
HRP20171640T1 (hr) 2018-01-12
US20120134994A1 (en) 2012-05-31
MX2011000455A (es) 2011-02-25
RU2546254C9 (ru) 2015-07-10
PT2365828E (pt) 2014-12-12
US9382324B2 (en) 2016-07-05
LT2842573T (lt) 2017-12-11
DK2842573T3 (da) 2017-10-30
BRPI0917315B8 (pt) 2021-05-25
DK2365828T3 (da) 2014-12-08
CA2733668A1 (en) 2010-05-14
JP2012508184A (ja) 2012-04-05
US10689448B2 (en) 2020-06-23
JP6445496B2 (ja) 2018-12-26
JP6960485B2 (ja) 2021-11-05
JP2014240385A (ja) 2014-12-25
WO2010054265A2 (en) 2010-05-14
RU2546254C2 (ru) 2015-04-10
KR101699432B1 (ko) 2017-01-24
US20180094063A1 (en) 2018-04-05
US8101723B2 (en) 2012-01-24
ES2646168T3 (es) 2017-12-12
JP2020096615A (ja) 2020-06-25
BRPI0917315B1 (pt) 2020-12-08
HK1249053A1 (zh) 2018-10-26
HUE035700T2 (en) 2018-05-28
PL2842573T3 (pl) 2018-04-30
US10138301B2 (en) 2018-11-27

Similar Documents

Publication Publication Date Title
DK3290052T3 (da) Monoklonale antistoffer mod fibroblastvækstfaktorreceptor 2
CY2019004I1 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
BRPI0918768A2 (pt) composições de anticorpo recombinante de anti-receptor do fator de crescimento epidérmico.
DK2066695T3 (da) Anti-myostatin-antistoffer
DK2131860T3 (da) Anti-sclerostin-antistoffer
BRPI0907532A2 (pt) Anticorpos anti-c5ar humanizados
BRPI0819165A2 (pt) Anticorpos anti-vegf
EP2331579A4 (en) MONOCLONAL ANTIBODIES
BRPI0814111A2 (pt) Anticorpo monoclonal citotóxico anticâncer
SG10201601279SA (en) Monoclonal Antibody STRO-4
BRPI0821777A2 (pt) Anticorpos biespecíficos bivalentes
BRPI0906877A2 (pt) Anticorpos anti-trkb aperfeiçoados
DK2344537T3 (da) Bispecifikke anti-vegf/anti-ang-2-antistoffer
CR20170001A (es) Anticuerpos anti factor d humanizados
IL204536A0 (en) Anti - il -6 receptor antibody
BRPI0923359A2 (pt) Anticorpos anti-igf
NO344963B1 (no) Humanisert antistoff
BRPI0821405A2 (pt) Anticorpos biespecíficos, bivalentes
BRPI0821375A2 (pt) Anticorpos biespecíficos, bivalentes
BRPI0819210A2 (pt) Anticorpos de proteína g anti-rsv
FI20075278A0 (fi) Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
BRPI0807991A2 (pt) Anticorpos anti-il-23r elaborados.
IL200168A0 (en) Monoclonal anti-cxcl13 antibodies
BRPI0817427A2 (pt) Anticorpo anti-bst2
BRPI0909633A2 (pt) anticorpos anti-tyrp1